Effect of topical 1.25% povidone-iodine eyedrops used for prophylaxis of ophthalmia neonatorum on renal iodine excretion and thyroid-stimulating hormone level

2006 ◽  
Vol 148 (3) ◽  
pp. 401-403 ◽  
Author(s):  
Ralph Richter ◽  
Harald Below ◽  
Ingrid Kadow ◽  
Axel Kramer ◽  
Cornelia Müller ◽  
...  
Keyword(s):  
Povidone Iodine ◽  
Hormone Level ◽  
Thyroid Stimulating Hormone ◽  
Ophthalmia Neonatorum ◽  
Iodine Excretion ◽  
Stimulating Hormone

Serum thyroid stimulating hormone level for predicting utility of thyroid uptake and scan

2020 ◽  
pp. 1-4
Author(s):  
Lauren Buehler ◽  
Alireza Movahed ◽  
Keren Zhou ◽  
M. Cecilia Lansang
Keyword(s):  
Hormone Level ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Uptake ◽  
Stimulating Hormone

scholarly journals Approach to Subclinical Thyroid Diseas

1970 ◽  
Vol 26 (2) ◽  
pp. 91-96
Author(s):  
Satya Ranjan Sutradhar
Keyword(s):  
Subclinical Hypothyroidism ◽  
Thyroid Dysfunction ◽  
Hormone Level ◽  
Elevated Serum ◽  
Thyroid Stimulating Hormone ◽  
Good Evidence ◽  
Reference Ranges ◽  
Mineral Density ◽  
Asymptomatic Patients ◽  
Stimulating Hormone

Subclinical thyroid dysfunction is defined as an abnormal serum thyroid-stimulating hormone level and free thyroxine and triiodothyronine levels within their reference ranges. The prevalence of subclinical hyperthyroidism is about 2 percent. Subclinical hypothyroidism is found in approximately 4 to 8.5 percent of the population. Most national organizations recommend against routine screening of asymptomatic patients, but screening is recommended for high risk populations. The management of subclinical thyroid dysfunction is controversial. There is good evidence that subclinical hypothyroidism is associated with progression to overt disease. Patients with a serum thyroid-stimulating hormone level greater than 10 mIU/L have a higher incidence of elevated serum low density lipoprotein cholesterol concentrations; however, evidence is lacking for other associations. There is insufficient evidence that treatment of subclinical hypothyroidism is beneficial. A serum thyroid stimulating hormone level of less than 0.1 mIU/L is associated with progression to overt hyperthyroidism, atrial fibrillation, reduced bone mineral density, and cardiac dysfunction. There is little evidence that early treatment alters the clinical course. DOI: 10.3329/jbcps.v26i2.4187 J Bangladesh Coll Phys Surg 2008; 26: 91-96

scholarly journals A STUDY ON RELATION OF THYROID STIMULATING HORMONE LEVEL WITH SKELETAL METASTASIS IN CARCINOMA PROSTATE PATIENTS

2017 ◽  
Vol 6 (79) ◽  
pp. 5619-5625
Author(s):  
Minaxi Sharma ◽  
Krishna Gopal Sharma ◽  
Deepak Sethi ◽  
Rajveer Singh ◽  
Anjali Sethi
Keyword(s):  
Hormone Level ◽  
Skeletal Metastasis ◽  
Thyroid Stimulating Hormone ◽  
Carcinoma Prostate ◽  
Stimulating Hormone

Aripiprazole Elevated the Thyroid-Stimulating Hormone Level and is Associated With Hyperprolactinemia

2020 ◽  
Vol 40 (4) ◽  
pp. 424-425
Author(s):  
Masum Öztürk ◽  
Şermin Yalın Sapmaz ◽  
Yekta Özkan ◽  
Hasan Kandemir
Keyword(s):  
Hormone Level ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone

scholarly journals Report of an association between race and thyroid stimulating hormone level.

1991 ◽  
Vol 81 (4) ◽  
pp. 505-506 ◽  
Author(s):  
J M Schectman ◽  
G A Kallenberg ◽  
R P Hirsch ◽  
R J Shumacher
Keyword(s):  
Hormone Level ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone
Sign in / Sign up

Export Citation Format

Share Document